Full Press Release Details
Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by
CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq:
LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute
(NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer.
part of the new clinical trial, listed as NCT06012734
at clinicaltrials.gov, LIXTE will provide its lead compound, LB-100, and Roche will
provide atezolizumab (Tecentriq , a PD-L1 inhibitor) through the imCORE Network, an academic-industry collaboration that aims to
accelerate cancer immunotherapy research through institution-sponsored studies.
is an exciting new clinical trial," said Neeltje Steeghs, M.D., Ph.D., medical oncologist from NKI and Antoni van Leeuwenhoek Hospital,
who is serving as principal investigator of the trial. "Only about 15% of colon cancers are responsive to immunotherapy, the so-called
MSI High cancers. However, approximately 85% of colon cancers are MSI Low where immunotherapy has no activity at all. If we are able
to sensitize these tumors to immunotherapy with LB-100, we could bring immunotherapy as an effective treatment option to a large group
of colon cancer patients."
van der Baan, LIXTE's Chief Executive Officer, said, "The ongoing interest in and support of this clinical trial underscores
the strength of the scientific rationale and potential of our lead compound, LB-100. This is the second recent clinical trial combining
LB-100 with immunotherapy that is supported by a major pharmaceutical company, following the start of a clinical trial earlier this year
that is being funded by GSK for the treatment of clear cell ovarian cancer."
is one of the world's leading comprehensive cancer centers. Ren Bernards, Ph.D., a leader in the field of molecular carcinogenesis
and Senior Staff Scientist at the Netherlands Cancer Institute, is a member of LIXTE's Board of Directors.
recent publication of new pre-clinical data in the journal EMBO Reports showed that LIXTE's lead compound, LB-100,
can turn immunologically "cold" tumors "hot," thereby potentially enhancing the response to immunotherapy. This
publication builds on a large body of scientific and emerging clinical evidence that LB-100 has strong synergy with checkpoint immunotherapy.
(atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated
in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com),
LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology - activation lethality -
that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept
clinical trials are currently in progress for colon, small cell lung and sarcoma cancers. Additional information about LIXTE can be found
Statement Disclaimer
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing
development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal
costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain
compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied
by words such as "intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other comparable terminology.
Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have
been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected
or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general
are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission
at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
more information about LIXTE, Contact: info@lixte.com
Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Inc. Investor Relations pwinvestor@pondel.com
Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962